Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins... Show more
ENTX is expected to report earnings to fall 1.43% to -13 cents per share on March 26
Q4'26
Est.
$-0.14
Q2'26
Missed
by $0.05
Q1'26
Beat
by $0.04
Q4'25
Beat
by $0.05
Q3'25
Beat
by $0.16
The last earnings report on August 10 showed earnings per share of -14 cents, missing the estimate of -9 cents. With 68.11K shares outstanding, the current market capitalization sits at 543.67M.